Is Eovist Suitable for Arterial-Phase MR Imaging of Liver
This trial has been completed.
|Treatments||eovist contrast, non eovist contrast|
|Sponsor||University of Michigan|
|Start date||December 2011|
|End date||August 2016|
|Trial size||198 participants|
|Trial identifier||NCT02684526, HUM00038856|
To examine the quality of liver images produced when the contrast agent Eovist is used during MRI.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
|Masking||single blind (outcomes assessor)|
|Primary purpose||basic science|
Scanning artifacts on MRI with Eovist
time frame: 5 years
Adverse events (including dyspnea)
time frame: 30 min
Male or female participants at least 21 years old.
- You have had a scheduled MRI(magnetic resonance imaging) scan using the contrast agent EOVIST.
- Male and females 21 years of age or older.
- Does not have a contraindication for MRI (e.g. cardiac pacemaker, ferromagnetic or metallic implants).
|Official title||Is Eovist Suitable for Arterial-Phase MR Imaging of Liver|
|Principal investigator||Hero Hussain, M.D.|
|Description||Researchers will review data from the Eovist MRI and compare the scan with previous MRI exams the patient had with the same or other contrast agents. To determine the efficacy of Eovist contrast agent in producing MRI images of the liver. We will monitor patients for any unusual symptoms (adverse events) when the contrast is given. Patients are asked to hold their breath during an MRI scan. Eovist may interfere with the "breath hold" which could result in more breathing artifacts (based on a qualitative scale) on arterial images when the patients are given Eovist vs. other contrast agents.|
Call for more information